Standout Papers

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Aci... 2003 2026 2010 2018 728
  1. Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer (2005)
    William Kevin Kelly, Owen A. O’Connor et al. Journal of Clinical Oncology
  2. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. (2003)
    Wm. Kevin Kelly, Victoria M. Richon et al. PubMed

Immediate Impact

1 by Nobel laureates 28 from Science/Nature 59 standout
Sub-graph 1 of 20

Citing Papers

Intercellular interaction dictates cancer cell ferroptosis via NF2–YAP signalling
2019 StandoutNature
A view on drug resistance in cancer
2019 StandoutNature
2 intermediate papers

Works of Tracy Curley being referenced

Potential Role of Histone Deacetylase Inhibitors in Mesothelioma: Clinical Experience with Suberoylanilide Hydroxamic Acid
2006
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer.
1993

Author Peers

Author Last Decade Papers Cites
Tracy Curley 1252 1082 324 1687 51 3.3k
Kenneth K. Iwata 953 1738 187 1921 49 3.4k
Martine P. Roudier 1735 1632 486 1293 69 3.4k
William K. Kelly 1429 992 456 796 49 2.7k
L. Rhoda Molife 1473 1257 227 1293 73 2.9k
Francesco Caponigro 1235 2276 395 1969 100 4.5k
David Chu 665 1044 139 1065 56 2.8k
Yan Chen 996 820 397 1297 89 2.6k
Michael Millward 1123 1718 139 1127 43 2.9k
Linda Janisch 733 2110 118 1730 68 3.5k
Paola Capodieci 551 1224 529 2176 30 3.6k

All Works

Loading papers...

Rankless by CCL
2026